| Does facial amimia impact the recognition of facial emotions? An EMG study in Parkinson’s disease S Argaud, S Delplanque, JF Houvenaghel, M Auffret, J Duprez, M Vérin, ... PLoS One 11 (7), e0160329, 2016 | 62 | 2016 |
| The many faces of apomorphine: lessons from the past and challenges for the future M Auffret, S Drapier, M Vérin Drugs in R&D 18, 91-107, 2018 | 51 | 2018 |
| Pharmacological insights into the use of apomorphine in Parkinson’s disease: clinical relevance M Auffret, S Drapier, M Vérin Clinical drug investigation 38, 287-312, 2018 | 48 | 2018 |
| Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations. VM Auffret M, Le Jeune F, Maurus A, Drapier S, Houvenaghel JF, Robert GH ... Journal of The Neurological Sciences (JNS), 279-287, 2017 | 36* | 2017 |
| Oral health disorders in Parkinson’s disease: more than meets the eye M Auffret, V Meuric, E Boyer, M Bonnaure-Mallet, M Vérin Journal of Parkinson's disease 11 (4), 1507-1535, 2021 | 34 | 2021 |
| Functional brain dysconnectivity in Parkinson's disease: a 5‐year longitudinal study S Yassine, U Gschwandtner, M Auffret, S Achard, M Verin, P Fuhr, ... Movement Disorders 37 (7), 1444-1453, 2022 | 21 | 2022 |
| New tricks for an old dog: A repurposing approach of apomorphine M Auffret, S Drapier, M Vérin European Journal of Pharmacology 843, 66-79, 2019 | 18 | 2019 |
| Evaluating cognitive action control using eye-movement analysis: an oculomotor adaptation of the simon task J Duprez, JF Houvenaghel, F Naudet, T Dondaine, M Auffret, G Robert, ... Frontiers in Human Neuroscience 10, 84, 2016 | 10 | 2016 |
| Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty M Auffret, D Weiss, F Stocchi, M Vérin, WH Jost Journal of Neural Transmission 130 (11), 1411-1432, 2023 | 7 | 2023 |
| Identification of Parkinson's disease subtypes from resting‐state electroencephalography S Yassine, U Gschwandtner, M Auffret, J Duprez, M Verin, P Fuhr, ... Movement Disorders 38 (8), 1451-1460, 2023 | 6 | 2023 |
| Enhanced Impulsive Action Selection in Middle-Aged Adults—Insights From an Oculomotor Simon Task J Duprez, JF Houvenaghel, S Argaud, F Naudet, T Dondaine, M Auffret, ... Frontiers in Aging Neuroscience 8, 251, 2016 | 6 | 2016 |
| French validation of the alcohol urge questionnaire: psychometric properties and relationship with alcohol dependence and drinking behavior A Constant, M Sanz, M Auffret, F Naudet, M Vérin, R Moirand Alcohol and Alcoholism 56 (3), 251-257, 2021 | 5 | 2021 |
| Genetic determinants associated with cfxA-positive clinical Capnocytophaga isolates Z Tamanai-Shacoori, A Dupont, M Auffret, V Peton, F Barloy-Hubler, ... International Journal of Antimicrobial Agents 46 (3), 356–358, 2015 | 4 | 2015 |
| Oral cavity disorders in Parkinson’s disease: more than meets the eye (P5. 8-038) M Auffret, V Meuric, E Boyer, M Bonnaure-Mallet, M Verin Neurology 92 (15_supplement), P5. 8-038, 2019 | 3 | 2019 |
| Traitements antiparkinsoniens oraux, les pratiques infirmières en EHPAD S Mazé, A Corvol, M Auffret Soins Gerontol 27 (153), 15-8, 2022 | 2 | 2022 |
| Management with apomorphine in Parkinson's disease M Auffret, S Drapier, M Vérin Diagnosis and Management in Parkinson's Disease, 461-475, 2020 | 2 | 2020 |
| Modes of death of hospitalized patients with Parkinson’s disease: a 12-year retrospective analysis (P2. 6-051) M Auffret, V Morel, G Robert, M Verin Neurology 92 (15_supplement), P2. 6-051, 2019 | 2 | 2019 |
| Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease J Duprez, JF Houvenaghel, S Drapier, M Auffret, D Drapier, G Robert, ... Journal of Neurology 265, 471-477, 2018 | 2 | 2018 |
| What was first and what is next in selecting device-aided therapy in Parkinson’s disease? Balancing evidence and experience O Phokaewvarangkul, M Auffret, S Groppa, V Markovic, I Petrovic, ... Journal of Neural Transmission, 1-14, 2024 | 1 | 2024 |
| Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort M Béreau, M Giffard, AL Clairet, G Degenne, L Tatu, E Richfield, E Magnin, ... Journal of Parkinson's disease 14 (1), 209-219, 2024 | 1 | 2024 |
Marc VérinProfesseur de Neurologie, Université de Rennes, Rennes, France在 chu-rennes.fr 的电子邮件经过验证
